The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
|Articles|July 1, 2001
Supplements and Featured Publications
- New Developments in the Treatment of Irritable Bowel Syndrome
- Volume 7
- Issue 8 Suppl
Irritable Bowel Syndrome: Toward a Cost-Effective Management Approach
Advertisement
Articles in this issue
over 25 years ago
Participating Facultyover 25 years ago
Introductionover 25 years ago
Defining and Diagnosing Irritable Bowel Syndromeover 25 years ago
Drug Therapy Options for Patients with Irritable Bowel Syndromeover 25 years ago
Continuing Medical Education Quizover 25 years ago
Selected AbstractsAdvertisement
Related to this article
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
5